Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Large Cell Lung Cancer

National Cancer Institute (NCI)Small moleculePhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Large Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 4A
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Vinorelbine
AIO-Studien-gGmbH
Phase 3BB
Gefetinib
National Cancer Institute (NCI)
Phase 3BB
Docetaxel
Korean South West Oncology Group
Phase 3BB

View all 34 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →